ATE503481T1 - Verwendung von 4-cyclopropylmethoxy-n-(3,5- dichlor-1-oxidopyridin-4-yl)-5-(methoxy)-pyridi - 2-carboxamid zur behandlung von rückenmarksverletzungen - Google Patents

Verwendung von 4-cyclopropylmethoxy-n-(3,5- dichlor-1-oxidopyridin-4-yl)-5-(methoxy)-pyridi - 2-carboxamid zur behandlung von rückenmarksverletzungen

Info

Publication number: ATE503481T1
Authority: AT; Austria
Prior art keywords: oxidopyridine; pyridi; cyclopropylmethoxy; carboxamide; dichloro
Prior art date: 2007-04-19

Application number

AT08787962T

Other languages

English (en)

Inventor

Philippe Delay-Goyet

Badia Ferzaz

Jocelyne Lolivier

Original Assignee

Sanofi Aventis

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-04-19

Filing date

2008-04-16

Publication date

2011-04-15

2008-04-16 Application filed by Sanofi Aventis filed Critical Sanofi Aventis

2011-04-15 Application granted granted Critical

2011-04-15 Publication of ATE503481T1 publication Critical patent/ATE503481T1/de

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)

AT08787962T 2007-04-19 2008-04-16 Verwendung von 4-cyclopropylmethoxy-n-(3,5- dichlor-1-oxidopyridin-4-yl)-5-(methoxy)-pyridi - 2-carboxamid zur behandlung von rückenmarksverletzungen ATE503481T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR0702851A FR2915098B1 (fr)	2007-04-19	2007-04-19	Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere
PCT/FR2008/000533 WO2008145840A2 (fr)	2007-04-19	2008-04-16	Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes de la moelle epiniere

Publications (1)

Publication Number	Publication Date
ATE503481T1 true ATE503481T1 (de)	2011-04-15

Family

ID=38779706

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT08787962T ATE503481T1 (de)	2007-04-19	2008-04-16	Verwendung von 4-cyclopropylmethoxy-n-(3,5- dichlor-1-oxidopyridin-4-yl)-5-(methoxy)-pyridi - 2-carboxamid zur behandlung von rückenmarksverletzungen

Country Status (33)

Country	Link
US (1)	US8592443B2 (de)
EP (1)	EP2150253B1 (de)
JP (1)	JP5386477B2 (de)
KR (1)	KR101470043B1 (de)
CN (1)	CN101674829B (de)
AR (1)	AR066106A1 (de)
AT (1)	ATE503481T1 (de)
AU (1)	AU2008257321B2 (de)
BR (1)	BRPI0810446A2 (de)
CA (1)	CA2684172C (de)
CL (1)	CL2008001134A1 (de)
CY (1)	CY1111779T1 (de)
DE (1)	DE602008005873D1 (de)
DK (1)	DK2150253T3 (de)
EA (1)	EA015355B1 (de)
ES (1)	ES2363056T3 (de)
FR (1)	FR2915098B1 (de)
HR (1)	HRP20110459T1 (de)
IL (1)	IL201451A (de)
JO (1)	JO2662B1 (de)
MA (1)	MA31369B1 (de)
ME (1)	ME00934B (de)
MX (1)	MX2009011285A (de)
MY (1)	MY146657A (de)
NZ (1)	NZ580483A (de)
PA (1)	PA8776601A1 (de)
PL (1)	PL2150253T3 (de)
PT (1)	PT2150253E (de)
PY (1)	PY08013253A (de)
SI (1)	SI2150253T1 (de)
TW (1)	TWI411435B (de)
UY (1)	UY31033A1 (de)
WO (1)	WO2008145840A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2915099B1 (fr)	2007-04-19	2009-06-05	Sanofi Aventis Sa	Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens
KR20150087252A (ko) *	2012-11-28	2015-07-29	사노피	4-(사이클로프로필메톡시)-n-(3,5-디클로로-1-옥시도피리딘-4-일)-5-메톡시피리딘-2-카복스아미드의 결정 형태의 제조 방법 및 이의 결정 형태
RU2635094C2 (ru) *	2012-11-28	2017-11-09	Санофи	Способ получения 4-(циклопропилметокси)-n-(3,5-дихлор-1-оксидо-4-пиридил)-5-метоксипиридин-2-карбоксамида
US20220226302A1 (en)	2021-01-20	2022-07-21	Altos Neuroscience, Inc.	Enhancement of camp signaling as a combination drug strategy for the treatment of depression and related conditions
WO2025079694A1 (ja) *	2023-10-12	2025-04-17	株式会社メドレックス	経皮吸収組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4193926A (en)	1974-03-20	1980-03-18	Schering Aktiengesellschaft	4-(Polyalkoxy phenyl)-2-pyrrolidones
ES2176251T3 (es)	1993-07-28	2002-12-01	Aventis Pharma Ltd	Compuestos utilizados como inhibidores de pde iv y del factor de necrosis tumoral(tnf).
GB9401460D0 (en)	1994-01-26	1994-03-23	Rhone Poulenc Rorer Ltd	Compositions of matter
GB9507297D0 (en)	1995-04-07	1995-05-31	Rh Ne Poulenc Rorer Limited	New composition of matter
US6196968B1 (en)	1997-06-02	2001-03-06	General Surgical Innovations, Inc.	Direct vision subcutaneous tissue retractor and method for use
US6177077B1 (en) *	1999-02-24	2001-01-23	Edward L. Tobinick	TNT inhibitors for the treatment of neurological disorders
WO2001047915A1 (en)	1999-12-23	2001-07-05	Icos Corporation	Cyclic amp-specific phosphodiesterase inhibitors
HUP0600103A2 (en)	2001-03-02	2006-06-28	Bristol Myers Squibb Co	Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
WO2004005258A1 (en)	2002-07-02	2004-01-15	Merck Frosst Canada & Co.	Di-aryl-substituted-ethane pyridone pde4 inhibitors
WO2004067006A1 (en)	2003-01-27	2004-08-12	Pharmacia Corporation	Combination of a pde iv inhibitor and a tnf-alpha antagonist
WO2005032493A2 (en) *	2003-10-07	2005-04-14	Renovis, Inc.	Amide compounds as ion channel ligands and uses thereof
WO2006135828A2 (en) *	2005-06-10	2006-12-21	Memory Pharmaceuticals Corporation	Trisubstituted amines as phosphodiesterase 4 inhibitors
US20070021451A1 (en) *	2005-07-20	2007-01-25	Hamamatsu University School Of Medicine	Method for preventing or treating neurologic damage after spinal cord injury

2007
- 2007-04-19 FR FR0702851A patent/FR2915098B1/fr not_active Expired - Fee Related
2008
- 2008-04-15 PA PA20088776601A patent/PA8776601A1/es unknown
- 2008-04-16 AT AT08787962T patent/ATE503481T1/de active
- 2008-04-16 KR KR1020097021624A patent/KR101470043B1/ko not_active Expired - Fee Related
- 2008-04-16 JP JP2010503548A patent/JP5386477B2/ja not_active Expired - Fee Related
- 2008-04-16 PL PL08787962T patent/PL2150253T3/pl unknown
- 2008-04-16 BR BRPI0810446-8A2A patent/BRPI0810446A2/pt not_active IP Right Cessation
- 2008-04-16 HR HR20110459T patent/HRP20110459T1/hr unknown
- 2008-04-16 DE DE602008005873T patent/DE602008005873D1/de active Active
- 2008-04-16 ES ES08787962T patent/ES2363056T3/es active Active
- 2008-04-16 CA CA2684172A patent/CA2684172C/fr not_active Expired - Fee Related
- 2008-04-16 EP EP08787962A patent/EP2150253B1/de active Active
- 2008-04-16 MY MYPI20094338A patent/MY146657A/en unknown
- 2008-04-16 PT PT08787962T patent/PT2150253E/pt unknown
- 2008-04-16 DK DK08787962.3T patent/DK2150253T3/da active
- 2008-04-16 NZ NZ580483A patent/NZ580483A/en not_active IP Right Cessation
- 2008-04-16 MX MX2009011285A patent/MX2009011285A/es active IP Right Grant
- 2008-04-16 AU AU2008257321A patent/AU2008257321B2/en not_active Ceased
- 2008-04-16 ME MEP-2009-298A patent/ME00934B/me unknown
- 2008-04-16 SI SI200830270T patent/SI2150253T1/sl unknown
- 2008-04-16 EA EA200970969A patent/EA015355B1/ru not_active IP Right Cessation
- 2008-04-16 CN CN2008800125419A patent/CN101674829B/zh not_active Expired - Fee Related
- 2008-04-16 WO PCT/FR2008/000533 patent/WO2008145840A2/fr not_active Ceased
- 2008-04-17 JO JO2008185A patent/JO2662B1/en active
- 2008-04-17 TW TW097114000A patent/TWI411435B/zh not_active IP Right Cessation
- 2008-04-18 UY UY31033A patent/UY31033A1/es not_active Application Discontinuation
- 2008-04-18 AR ARP080101600A patent/AR066106A1/es unknown
- 2008-04-18 CL CL2008001134A patent/CL2008001134A1/es unknown
- 2008-04-18 PY PY200808013253A patent/PY08013253A/es unknown
2009
- 2009-10-05 US US12/573,316 patent/US8592443B2/en not_active Expired - Fee Related
- 2009-10-11 IL IL201451A patent/IL201451A/en not_active IP Right Cessation
- 2009-11-10 MA MA32335A patent/MA31369B1/fr unknown
2011
- 2011-06-28 CY CY20111100611T patent/CY1111779T1/el unknown

Also Published As

Publication number	Publication date
MX2009011285A (es)	2009-11-02
US8592443B2 (en)	2013-11-26
IL201451A (en)	2013-04-30
HK1142000A1 (en)	2010-11-26
CA2684172C (fr)	2015-10-27
WO2008145840A3 (fr)	2009-06-25
MY146657A (en)	2012-09-14
CA2684172A1 (fr)	2008-12-04
KR20090130063A (ko)	2009-12-17
KR101470043B1 (ko)	2014-12-05
PA8776601A1 (es)	2008-11-19
FR2915098B1 (fr)	2009-06-05
PY08013253A (es)	2013-08-01
AU2008257321B2 (en)	2013-08-15
EA200970969A1 (ru)	2010-02-26
DE602008005873D1 (de)	2011-05-12
AR066106A1 (es)	2009-07-22
MA31369B1 (fr)	2010-05-03
CL2008001134A1 (es)	2009-01-16
US20100137370A1 (en)	2010-06-03
NZ580483A (en)	2011-06-30
HRP20110459T1 (hr)	2011-07-31
JP5386477B2 (ja)	2014-01-15
AU2008257321A1 (en)	2008-12-04
CN101674829B (zh)	2012-01-18
PT2150253E (pt)	2011-06-17
TWI411435B (zh)	2013-10-11
ES2363056T3 (es)	2011-07-19
BRPI0810446A2 (pt)	2014-10-14
SI2150253T1 (sl)	2011-07-29
EP2150253B1 (de)	2011-03-30
CN101674829A (zh)	2010-03-17
EA015355B1 (ru)	2011-06-30
EP2150253A2 (de)	2010-02-10
TW200911248A (en)	2009-03-16
IL201451A0 (en)	2010-05-31
CY1111779T1 (el)	2015-10-07
WO2008145840A2 (fr)	2008-12-04
UY31033A1 (es)	2008-11-28
PL2150253T3 (pl)	2011-08-31
JP2010524905A (ja)	2010-07-22
FR2915098A1 (fr)	2008-10-24
JO2662B1 (en)	2012-06-17
ME00934B (me)	2012-06-20
DK2150253T3 (da)	2011-07-25

Legal Events

Date

Code

Title

Description

2012-01-15

UEP

Publication of translation of european patent specification

Ref document number: 2150253

Country of ref document: EP

Publication	Publication Date	Title
EP3861968C0 (de)	2023-09-06	Vorrichtungen zur behandlung von schlafapnoe
EP1758597A4 (de)	2008-02-27	Verwendung von arzneimittelkombinationen zur behandlung der insulinresistenz
DE602006019560D1 (de)	2011-02-24	2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
EP3871639C0 (de)	2024-06-05	Vorrichtung zur behandlung von gastroösophagealer refluxkrankheit
ATE527241T1 (de)	2011-10-15	Pyridiazinonderivate zur behandlung von tumoren
EP2135858A4 (de)	2012-02-08	Zusammensetzung zur behandlung von infektionserkrankungen
ATE429218T1 (de)	2009-05-15	Pinolensäure zur behandlung von übergewicht
ATE521365T1 (de)	2011-09-15	Kinin-antagonisten zur behandlung von blasenfunktionsstörung
DE602006019468D1 (de)	2011-02-17	Diarylharnstoffe zur behandlung von pulmonaler hypertonie
EP2249765A4 (de)	2012-09-05	Dapson zur behandlung von rosascea
DE502005010499D1 (de)	2010-12-23	Implantat zur Behandlung von Fettsucht
DE602006009899D1 (de)	2009-12-03	Verwendung von oxycodon zur behandlung von viszeralem schmerz
DE602008005873D1 (de)	2011-05-12	Verwendung von 4-cyclopropylmethoxy-n-(3,5-dichlor-1-oxidopyridin-4-yl)-5-(methoxy)-pyridin-2-carboxamid zur behandlung von rückenmarksverletzungen
EP1863520A4 (de)	2009-10-21	Verwendung von interleukin 17e zur behandlung von krebs
ATE516805T1 (de)	2011-08-15	Medikament zur behandlung von endometriose
ATE504297T1 (de)	2011-04-15	Visnadin zur behandlung von kopfhautjucken
DE602006017367D1 (de)	2010-11-18	Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
DE602006003094D1 (de)	2008-11-20	4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DE602006007323D1 (de)	2009-07-30	VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
DE602005016141D1 (de)	2009-10-01	S-mirtazapin zur behandlung von hitzewallungen
DE502007006880D1 (de)	2011-05-19	Verwendung von gallium (iii) komplexen zur behandlung von melanomen
ATE347883T1 (de)	2007-01-15	Verwendung von n-(2-aryl-propionyl)-sulfonamiden zur behandlung von rückenmarkverletzungen
ATE513548T1 (de)	2011-07-15	Verwendung von 4-cyclopropylmethoxy-n-(3,5- dichlor-1-oxidopyridin-4-yl)-5-(methoxy-)pyridi - 2-carboxamid zur behandlung motorischer störungen aufgrund der parkinsonschen krankheit
DE602005027251D1 (de)	2011-05-12	Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen
ATE532513T1 (de)	2011-11-15	Verwendung von 4-cyclopropylmethoxy-n-(3,5- dichlor-1-oxidopyridin-4-yl)-5-(methoxy)-pyridi - 2-carboxamid zur behandlung von schädeltraumata